A six-patient series described better mask acceptance during dexmedetomidine treatment. Its favorable respiratory narrative was not a controlled comparative safety result.
Distressed patients with COVID-19 or COPD had difficulty tolerating a tight-fitting noninvasive-ventilation mask. The report described lower agitation scores and improved mask acceptance after dexmedetomidine was added.
Midazolam and other sedatives were discussed as alternatives in the background, but the series did not randomly assign comparator treatment.
Oxygenation can improve when effective ventilation becomes possible, without proving that one medicine directly improved lung function. Changes in disease, respiratory support, and other treatment can also contribute.
Six selected cases cannot establish that respiratory depression never occurs or determine how often intubation was prevented. The paper supports a clinical hypothesis about tolerance, not proof that dexmedetomidine is safer than every benzodiazepine regimen or that substituting it would have avoided an individual adverse event.
Original analysis of the supplied journal article, identified as PMC9938913.